Key result
Icosapent ethyl yielded more in-trial quality-adjusted life-years than standard care (MD 0.07; 95% CI 0.01-0.12) and was projected to be cost-saving over a lifetime using SSR Health net costs.
Why the study?
Following demonstrated efficacy of icosapent ethyl in REDUCE-IT, its cost-effectiveness compared with standard care in high-risk patients with hypertriglyceridemia despite statin treatment remained to be estimated.
Does icosapent ethyl improve cost-effectiveness compared to standard care in high-risk patients with hypertriglyceridemia despite statin treatment?
RCT (n=8,179)
randomly assigned
Does icosapent ethyl improve cost-effectiveness compared to standard care in high-risk patients with hypertriglyceridemia despite statin treatment?
Mean Difference: 0.07 (95% CI 0.01–0.12)
Absolute Event Rate: 3.34% vs 3.27%
Icosapent ethyl provides better cardiovascular outcomes and is cost-effective or cost-saving compared to standard care in high-risk patients with hypertriglyceridemia on statins at common willingness-to-pay thresholds.
No takes yet. Share an insight, caveat, or question.
May support IPE consideration at net costs below $100k/QALY in REDUCE-IT patients; leaves open real-world value at varying prices.
Weintraub et al. (2022) conducted an RCT in Hypertriglyceridemia despite statin treatment (n=8,179). Icosapent ethyl vs. placebo was evaluated on incremental quality-adjusted life-years (QALYs) (MD 0.07, 95% CI 0.01-0.12). Icosapent ethyl yielded more in-trial quality-adjusted life-years than standard care (MD 0.07; 95% CI 0.01-0.12) and was projected to be cost-saving over a lifetime using SSR Health net costs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: